anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants received single oral dose of Mirabegron 25 milligrams (mg) tablet once daily, at the same time after a meal for a duration of 12 weeks. Dose escalation to 50 mg was permitted at Visit 3 (Week 4) or Visit 4 (Week 8) at the discretion of investigator.
Monoclonal antibodies manifesting specific reactivity to benign adenomatous polyps of the human colon are produced. Hybridoma technology was utilized to produce immunoglobulin producing cell lines. Splenic lymphocytes from mice, immunized with a membrane fraction derived from human tubular adenomatous colonic polyps, were fused with a mouse non immunoglobulin secreting myeloma cell line (NS-1). Screening of hybridoma culture supernatant for positive reactivity with adenomatous colonic polyp extract, and negative activity with extracts from normal liver and spleen allowed for selection of desired immunoglobulin producing cultures. Further screening of expanded cultures with extracts of colorectal cancer, apparently normal mucosa adjacent to the cancer, and a variety of normal human extracts allowed further distinctions in binding reactivity. One such selected cell line produced a monoclonal antibody designated Adnab-9 selected on this basis. Adnab-9 was reacted with colonic-washing effluent derived from patients undergoing routine precolonoscopic bowel cleansing and the resultant mean binding activity in the effluent of patients proved to have a colorectal cancer was significantly elevated with respect to those with an apparently normal colon. Since Adnab-9 binding may be increased in some colorectal cancer patients with early stage disease, Adnab-9 aids in the diagnosis, and timely treatment of colorectal cancer.
The control group accessed the NEA 'Stop Dengue' website which contained dengue prevention information in the forms of online articles, posters and video. The participants were instructed to complete reading the online resources within 2 weeks.
Who can participate? Patients aged 6 months to 16 years with relapsed acute myeloid leukaemia ahead of a planned bone marrow transplant.

What does the study involve? Patients will undergo careful screening to confirm that this treatment is adequate for them. Chemotherapy will be given prior to BE CAR-33 infusion to improve the ability of T-cells to establish and grow. Patients will then receive a single infusion of the BE CAR-33 cells. They will be closely monitored via blood and bone marrow tests for safety and to check the levels of BE CAR-33 and leukaemia cells. The investigators expect patients to be in hospital for 5 weeks for the BE CAR-33 therapy and the transplant will be scheduled 4 weeks after the end of BE CAR33. Patients will be monitored every month for the first three months and then every 6 months.

What are the possible benefits and risks of participating? Taking part in the study of testing 'ready-made' CAR T cells could help reduce the amount of disease and get the patient into remission before a planned bone marrow transplant. Leukaemia is less likely to come back after a bone marrow transplant if levels in the bone marrow are undetectable. The ready-made CAR T cells are being used to try and improve the chances of successful transplantation. Side effects may include low blood cell counts, infections, cytokine storm (severe immune reaction), graft versus host disease (where the donated cells attack the body) and other complications.
BACKGROUND: Vancomycin-associated acute kidney injury (VA-AKI) is the most clinically relevant side effect of vancomycin. The objective of this study was to investigate the association between VTC and VA-AKI as well as 30-day mortality in critically ill elderly adults.
METHOD: Elderly patients with trough serum vancomycin concentration records(VTC) in the Medical Information Mart-IV (MIMIC-IV) and eICU databases were retrospectively studied.
RESULTS: A total of 3,146 critically ill elderly adults were finally enrolled. The incidence of VA-AKI in the elderly population was 76.5%. Logistic regression analysis revealed significant relationships between VA-AKI and various factors, including VTC, comorbidities, and laboratory indicators, and SOFA, and GCS score. For each mg/L increase, the OR for VA-AKI increased by 2.5%. The association between VTC and 30-day mortality was found to be statistically significant (odds ratio (OR): 1.021, 95% CI: 1.010-1.031), P < 0.001). The Restricted cubic splines (RCS) curves revealed that VTC ranged of 19.67 to 35.72 mg/l for AKI and 19.17 to 42.86 mg/l for 30-day mortality exhibit OR with 95% CI above 1, indicating statistically significant associations with an increased risk of AKI and 30-day mortality, respectively. In the subgroup analysis, VTC was identified as a risk factor for VA-AKI in specific patient groups, including white individuals, female patients, those with shock, patients with SOFA > 6, patients with baseline creatinine > 1.2 mg/dl and patients with or without exposed to other nephrotoxic medications.
CONCLUSION: This study found the significant association between VTC and the incidence of VA-AKI and 30-day mortality in critically ill elderly adults. The RCS curves indicated concentration ranges for AKI (19.67-35.72 mg/L) and 30-day mortality (19.17-42.86 mg/L), signifying increased risk.
Participants with no history of SARS-COV-2 infection. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
Chronic urticaria, defined by its persistence beyond 6 weeks, is a common condition (0.1% to 3% of the general population), occurring at any age. The etiology is not found in nearly 75% of cases (chronic idiopathic urticaria). Chronic idiopathic urticaria may resolve over several months or years. The quality of life of patients is usually strongly spoiled. The gold standard treatment consist of anti-H1 molecules. In severe cases, which are refractory to anti-H1, few therapeutic alternatives exist. Two studies have shown a benefit when adding to anti-H1, montelukast, anti-leukotriene, or cyclosporine. Methotrexate, which is another immunosuppressive drug, cheap and commonly prescribed by dermatologists, has been efficient in severe chronic urticaria, in an open study and in few case reports.

Methotrexate, an anti-metabolite drug which inhibits dihydrofolate reductase, is indicated in hematologic malignancies and in autoimmune diseases. It may be given by oral or parenteral administration, once a week, and requires regular monitoring of renal and hepatic function, and blood count.
Theories of reading posit that decisions about "where" and "when" to move the eyes are driven by visual and linguistic factors, extracted from the perceptual span and word identification span, respectively. We tested this hypothesized dissociation by masking, outside of a visible window, either the spaces between the words (to assess the perceptual span, Experiment 1) or the letters within the words (to assess the word identification span, Experiment 2). We also investigated whether deaf readers' previously reported larger reading span was specifically linked to one of these spans. We analyzed reading rate to test overall reading efficiency, as well as average saccade length to test "where" decisions and average fixation duration to test "when" decisions. Both hearing and deaf readers' perceptual spans extended between 10 and 14 characters, and their word identification spans extended to eight characters to the right of fixation. Despite similar sized rightward spans, deaf readers read more efficiently overall and showed a larger increase in reading rate when leftward text was available, suggesting they attend more to leftward information. Neither rightward span was specifically related to where or when decisions for either group. Our results challenge the assumed dissociation between type of reading span and type of saccade decision and indicate that reading efficiency requires access to both perceptual and linguistic information in the parafovea. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Simvastatin is a lipid-lowering agent that is derived synthetically from a fermentation product of Aspergillus terreus. After oral ingestion, simvastatin, which is an inactive lactone, is hydrolyzed to the corresponding β-hydroxyacid form. This is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol.

Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1α,3α,7β,8β(2S*,4S*),-8aβ]]. The molecular formula of simvastatin is C25H38O5 and its molecular weight is 418.57. Its structural formula is:

Simvastatin, USP is a white to off-white powder that is practically insoluble in water; freely soluble in chloroform, in methanol and in alcohol; sparingly soluble in propylene glycol; very slightly soluble in hexane.

Each simvastatin tablet intended for oral administration contains 5 mg or 10 mg or 20 mg or 40 mg or 80 mg of simvastatin. In addition, each tablet contains following inactive ingredients: ascorbic acid, citric acid anhydrous, hydroxypropyl cellulose, hypromellose, lactose anhydrous, magnesium stearate, pregelatinized starch, talc and titanium dioxide. Additionally each 10 mg tablet contains iron oxide red and iron oxide yellow, 20 mg tablet contains iron oxide black, iron oxide red and iron oxide yellow and 40 mg tablet contains iron oxide red. Butylated hydroxyanisole is added as a preservative. The botanical source for Pregelatinized starch is corn starch.
FIELD: medicine, dermatology. SUBSTANCE: invention relates to skin diseases and can be used in treatment of acne disease. Method of treatment of acne disease involves application of bandage on the lesion focus wetted with bromine-iodine mother brine from the health resort Ust-Kachka as a medicinal agent with the total mineralization 260-290 g/l at t = 24-25 C, once per a day for 10-15 min and the following exposition of damaged skin site with mother brine. Treatment course involves 9-12 procedures. EFFECT: enhanced effectiveness of treatment. 3 ex
Central sensitization refers to persistent post-injury changes in the central nervous system resulting in greater pain sensitivity. The concept of preemptive analgesia is defined as a treatment that prevents establishment of central sensitization by providing analgesic coverage during the perioperative period of surgery. Previous acute pain studies using the oral surgery model have shown that suppression of postoperative pain, not intra-operative nociceptive barrage, diminishes the development of sensitization at 24 to 48 hours post-surgery. During the intermediate postoperative period, the nociceptive input from both surgical insult and inflammation leads to central sensitization, yet their relative contributions have not been clearly evaluated. The proposed study is designed to evaluate the relative impact of surgical insult and the subsequent inflammation on postoperative pain. The relative contribution of each of these nociceptive processes provides a basis for postoperative pain management and the development of preemptive strategies.

All subjects (N = 136) will be healthy volunteers scheduled for third molar extractions. Using a double-blinded, randomized, parallel study design, subjects will be randomized into four groups. All patients will receive local anesthesia injections preoperatively (either 2% lidocaine or 0.5% bupivacaine) to manage surgical pain in conjunction with a preemptive medication (either 50 mg of rofecoxib or placebo) to control postoperative inflammation. The first dose of preemptive medication will be taken by mouth 90 minutes prior to conscious sedation and extractions, and later self-administered once a day for the next 48 hours. The analgesic effect of the drugs will be assessed in the clinic every 20 minutes for the first four hours after extractions, and then self-assessed at 24, and 48 hours after surgery using two pain intensity assessment instruments: category scale and visual analog scale (VAS). Microdialysis will be performed with sample collection concurrent with pain report over the immediate postoperative period of four hours. Two biopsies will be performed: preoperatively, and postoperatively at 48 hours. The combination regimen with bupivacaine and rofecoxib is predicted to maximally suppress the onset and intensity of postoperative dental pain to a greater extent than all other groups through a blockade of the nociceptive input from both surgery and inflammation. It is hypothesized that this preemptive treatment will maximally inhibit the development of central sensitization following tissue injury which manifests as hyperalgesia at later time points. It is also hypothesized that the administration of rofecoxib (a cyclooxygenase-2 selective anti-inflammatory medication) will reduce post-surgical pain experienced at later time points to a greater extent than suppression of the intra-operative nociceptive barrage alone (by bupivacaine), suggesting that suppression of inflammation plays a more pivotal role than attenuating nociception due to tissue injury in diminishing central sensitization.
The invention relates to a preparation method of a traditional Chinese medicine composition capable of effectively removing hand verruca plana. A plurality of interaction relationships such as interpromoting relation, mutual promotion, incompatibility and mutual-detoxication among the raw materials of the traditional Chinese medicines are balanced according to the theory of the traditional Chinese medicine science, and the therapeutic principle refers to dispelling mild wind, eliminating dampness, removing toxins and removing warts. The traditional Chinese medicine composition abides by the drug properties on the aspect of raw material formula, focuses on the effects of dispelling wind and eliminating dampness, takes the overall balance into consideration and aims to remove toxins and warts. In the traditional Chinese medicine composition, herba equiseti hiemalis has the effects of dispelling wind and heat and resolving the flesh; semen coicis, folium isatidis, burdock and phaseolus calcaratus are used for clearing away heat and toxic materials; pine nodular branch is used for expelling wind-damp; duckweed has the effect of dispersing wind-heat; rhizoma zingiberis and safflower are used for relaxing meridians; and calamine is used for relieving itching and healing sore. The above traditional Chinese medicines are combined according to syndrome differentiation and supplement each other in action, and the medicines directly act on the focuses of infection, thereby effectively playing the roles in dispelling wind, eliminating dampness, and detoxifying and removing warts. Especially, the traditional Chinese medicine composition is good in treatment effect on plane warts on faces.
The recommended dosage of TEPMETKO is 450 mg orally once daily with food [see Clinical Pharmacology (12.3)] until disease progression or unacceptable toxicity.

Instruct patients to take their dose of TEPMETKO at approximately the same time every day and to swallow tablets whole. Do not chew, crush or split tablets. Patients who have difficulty swallowing solids can disperse tablets in water [see Dosage and Administration (2.3)].

Advise patients not to make up a missed dose within 8 hours of the next scheduled dose.

If vomiting occurs after taking a dose of TEPMETKO, advise patients to take the next dose at the scheduled time.
1. A method of administering taxane to a patient in need of treatment with taxane comprising administering a pharmaceutical composition over a period of less than an hour in an amount from about 75 to 300 mg/m2 wherein said pharmaceutical composition is liposomal encapsulated taxane or an antineoplastic derivative thereof. 2. The method of claim 1 wherein said taxane is selected from the group consisting of paclitaxel. 3. The method of claim 1 or 2 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 4. The method of claim 1 or 2 wherein said pharmaceutical composition further comprises cardiolipin. 5. The method of claim 4 wherein said cardiolipin is selected from the group consisting of natural cardiolipin and synthetic cardiolipin. 6. The method of claim 1 or 2 wherein said amount of said taxane is about 135 mg/m<2>. 7. The method of claim 1 or 2 wherein said amount of said taxane is about 175 mg/m<2>. 8. The method of claim 1 or 2 wherein said amount of said taxane is about 250 mg/m<2>. 9. The method of claim 1 or 2 wherein said amount of said taxane is about 300 mg/m<2>. 10. The method of claim 1 or 2 wherein said liposomal encapsulated taxane is administered by intravenous infusion. 11. The method of claim 10 wherein said liposomal encapsulated taxane is administered over a period of 45 minutes. 12. The method of claim 10 wherein said administration of said liposomal encapsulated taxane is repeated at least once every 21 days. 13. The method of claim 1 or 2 wherein a patient in need of treatment with taxane is human, said liposomal encapsulated taxane being administering in less than 3 hours in quantity of from 90 to 300 mg/m<2>. 14. The method of claim 13 wherein said taxane is administered intravenously. 15. The method of claim 13 in which the liposomal taxane is administered as a single agent without pretreatment by steroids, antihistamines or other therapeutic agents. 16. The method of claim 13 in which substantial nonhematological toxicity is not induced. 17. The method of claim 13 in which substantial anaphylaxis is not induced. 18. The method of claim 13 in which said taxane is administered in less than 1 hour. 19. The method of claim 13 in which said taxane is administered in about 45 minutes. 20. The method of claim 13 further comprising repeating the step of administering rapidly a large quantity of liposomal taxane to a human without inducing substantial hematological or nonhematological toxicity. 21. The method of claim 20 wherein the repeating step occurs in 21 days. 22. A method of treating a human with taxane comprising intravenously administering to a human in about 45 minutes about 175 to 300 mg/m<2> of a liposomal taxane formulation that has a dose limiting toxicity of 18 at least about 300 mg/m<2> when administered in about 45 minutes.
OBJECTIVE: Dysphagia is a common complication associated with cardiovascular surgery (CVS). This study sought to better understand recovery timelines, identify risk factors, and create a prognostic model for oral intake restoration.
METHODS: This retrospective study included 134 patients who had CVS between April 2022 and March 2024. We assessed swallowing ability through fiberoptic endoscopic evaluation of swallowing (FEES). We randomly divided the patients' data into a training dataset and a test dataset in a ratio of 70/30 and Kaplan-Meier analyses and Cox regression were used to assess predictors of total oral intake. We also created a scoring system using the estimated regression coefficients.
RESULTS: Most patients with CVS achieved total oral intake in 7-11 days after extubation. Over 168 h of intubation, the presence of penetration or aspiration, a poor FEES score (score > 6), and perioperative complications were significant risk factors for delayed total oral intake. The predicting score was calculated by adding the scores for each individual factor, including FEES score, penetration/aspiration, and preoperative complications. Scores ranged 0-8, categorizing patients into 0-2, 3-5, and 6-8 groups, clearly demonstrating that the higher the predicting score, the longer the time to total oral intake in both the training and the test dataset.
CONCLUSIONS: All risk factors for unsuccessful or delayed total oral intake were intubation for more than a week, poor swallowing ability, and the presence of perioperative complications. The scoring system accurately predicts the restoration of oral intake following CVS.
Patients randomised to the standard of care IV group will receive a single, 45-minute stimulation from a sham remote electrical neuromodulation (REN) device, which will not administer the typical electrical stimulation (modulated frequency of \~ 0.083 Hz and a modulated pulse width of 40-550 µs), and will be given a single dose IV ketorolac and IV metoclopramide, at a dose of 0.5 mg/kg (for a maximum 30 mg) and 0.15 mg/kg (for a maximum 10mg), respectively. Metoclopramide will be infused over 15-30 minutes and ketorolac will be administered as a direct IV push over 1-5 minutes.
The present invention relates to a traditional Chinese medicine, particularly to a traditional Chinese medicine eye drop for treating eye diseases and a preparation method thereof. The traditional Chinese medicine is mainly prepared by making sesame oil, scorpions, centipedes and earthworms into drops by using special technology. Through clinical observation, the traditional Chinese medicine has a wide medicine treating range and can treat ceratonosus, iritis and secondary glaucoma. Through clinical practices for scores of years, the traditional Chinese has the effective rate of 100%, the cure rate of 96% and the rest rate of 4%. The present invention is prepared into drops by using traditional Chinese medicines by aiming at the characteristics of various intractable eye diseases, and the traditional Chinese medicine has optimum curative effect on treating various intractable diseases in ophthalmology department. After long term clinical observation, the traditional Chinese medicine has the advantages of no poison, no side effect and no generation of drug tolerance.
Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
The embodiments of the present invention provide herbal syrup comprising  Nigella sativa  ( Nigella ) seed extract and  Zingiber officinale  (ginger) root extract. The  Nigella  seeds and ginger roots are identified in a herbarium and confirmed. The  Nigella  seeds and ginger roots are cleaned and disinfected. After disinfection the  Nigella  seeds and ginger roots are grinded separately to obtain powder. The powders of  Nigella  seed and ginger root are treated in a percolator machine to extract thymoquinone and gingerol. The  Nigella  seed extract and ginger extract are mixed and herbal syrup is made for the patients with abnormal sperm parameters. The dosage of the herbal syrup is 7 ml. The syrup is administered daily during breakfast for 4 months. The sperm count increases gradually from 15 million/ml, 43 million/ml, 89 million/ml and 120 million/ml after four month of administration.